Log in to your Inderes Free account to see all free content on this page.
Spago Nanomedical
0.206
SEK
+5.1 %
SPAGO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+5.1%
+5.1%
+19.08%
-7.21%
-27.46%
-37%
-95.44%
-98.46%
-98.19%
Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.
Read moreMarket cap
71.73M SEK
Turnover
8.76K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
6.2.
2025
Annual report '24
7.5.
2025
Interim report Q1'25
20.8.
2025
Interim report Q2'25
ShowingAll content types
Second patient group successfully dosed in Spago Nanomedical's Phase I/IIa study Tumorad-01
Spago Nanomedical interim report January-September 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio